Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-07-31

Clinical Trial Results: Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 dose-confirmation study of FLT180a in Hemophilia B was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • FLT180a (FLT180a)

Snippet

Sponsor: Spur Therapeutics | Conditions: Hemophilia B | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-07-31